instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: The 10,000 or so people who remain on Ambae island have mixed feelings about the plans. Some who are badly affected by the ash are eager to leave while others are resisting losing their land and culture. The island was temporarily evacuated last September when the eruption cycle began. This time, authorities are planning a permanent move. Government spokesman Hilaire Bule told The Associated Press on Thursday that he expects the Council of Ministers to approve a relocation plan by next week. Bule said the islanders would be offered residence on two neighboring islands. “It’s not an easy decision,” Bule said. He said there were many details to work through, including providing schools and facilities to the displaced residents and negotiating land and new homes for them. Many people have close family and spiritual ties to the islands where they’ll be relocated, Maewo and Pentecost, Bule said. Traditional religion even has it that the islands are part of a family — Pentecost being the mother, Maewo the father and Ambae the son. Most people on Ambae live a subsistence lifestyle by farming and fishing. Already hundreds of people have moved to temporary shelters on parts of the island that are not so affected by the ash. Ambae is about 400 square kilometers (154 square miles) and is one of about 65 inhabited islands in Vanuatu, which is home to 280,000 people. Vanuatu sits on the Pacific’s “Ring of Fire,” the arc of seismic faults around the Pacific Ocean where earthquakes and volcanoes are common. Brad Scott, a New Zealand volcanologist with GNS Science who has been seconded to help Vanuatu authorities, said more than one-quarter of Ambae has been severely impacted, with many traditional thatch roofs collapsing under the weight of the thick ash. He said traditional gardens have been buried and killed in some places and water supplies have been discolored and the water tastes strange. He said there is lots of fine-grained ash, which can affect people’s breathing and respiratory functioning. Other countries including France, New Zealand and Australia provided aid and financial help for the earlier evacuation. Australia on Thursday announced it was providing 300,000 Australian dollars ($226,000) to help with the island’s permanent evacuation, with a focus on the needs of women, children and people with disabilities. Despite the problems, Scott said, many people want to stay put. “There has been significant pushback in the community,” Scott said. “Some people, suffering from significant ash fall, would love to be anywhere else on the planet. Others have strong cultural associations.” Scott said the Manaro volcano on Ambae island had a large eruption about 400 years ago and has had several smaller eruptions over the past 100 years. There have been three phases in the current eruption, with the most recent phase, which started in March, producing the most ash. He said the volcano has actually quietened down over the past two weeks, although there is no way of predicting if and when the next explosive phase would begin. Asked if there was a chance that the residents might be able to one day move back to the island, Bule, the government spokesman, said that was not a question for him. “We don’t know,” he said. “You’ll have to ask the volcano.” Claim: Vanuatu plans to permanently evacuate entire volcanic island.
answer:
The Pacific nation of Vanuatu is preparing to permanently evacuate the entire population of one of its islands as thick ash spewing from a volcano kills crops, dirties water supplies and fouls the air.


question:
Paragraph: A 38-year-old man from Zunyi city died last Thursday, Xinhua said, citing health authorities in Guizhou. Xinhua said it was the first human case of H7N9 in Guizhou this year. Last Friday, China said a 38-year-old man in eastern Fujian province died from H7N9. The World Health Organisation (WHO) said last week that seven more people in China had been found to be infected with the H7N9 strain of bird flu in the previous week, taking to around 150 the total number of cases so far. The H7N9 bird flu emerged last year in China and has infected around 150 people there and in Taiwan and Hong Kong, killing at least 45 of them. Experts say there is no evidence as yet of any easy or sustained person-to person transmission of the strain. But an early scientific analysis of probable transmission of the new flu from person to person, published last August, gave the strongest proof yet that it can at times jump between people and so could cause a human pandemic. The WHO said the source of the human infections was still being investigated. It stressed that it does not advise any special screening for people going in and out of China, nor does it recommend any travel or trade curbs. Claim: China reports second H7N9 bird flu death in a week.
answer:
China reported one more death from the H7N9 strain of bird flu in southwestern Guizhou province, state news agency Xinhua said on Monday, in the second death from the virus in the past week.


question:
Paragraph: The panel voted 16 to 1 in favor of the drug, Northera, for patients with neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that occurs on standing and is associated with certain neurological disorders such as Parkinson’s disease. Chelsea shares more than doubled in after-hours trading. The FDA is not bound to follow the advice of its panels but typically does so. Panelists wrestled with gaps in the clinical data which they said made it difficult to determine whether the drug, which appears effective after one week’s treatment, is effective over the long term. Most suggested the company be required to conduct a follow-up study to prove a durable benefit. Dr. James de Lemos, a cardiologist and professor of medicine at the University of Texas Southwestern Medical Center, said he voted in favor “based on the compelling evidence of suffering and the absence of viable alternatives,” but said the approval should be conditional on further study. Patients and patient advocates testified before the panel about the positive impact the drug has had on their lives. Gail Hershkowitz, 65, a retired music teacher who lives in Boynton Beach, Florida, was diagnosed with Parkinson’s disease 15 years ago and, later, with NOH. She said in an interview that she became afraid to leave her house after fainting and vomiting multiple times in public. She took Northera as part of a clinical trial and says it has enabled her to lead a relatively normal life. But some panelists expressed frustration that the experience of patients who have benefited from the drug was not clearly backed up by data from the clinical trials. A reviewer for the FDA, Dr. Shari Targum, said in preparatory documents published on Friday that she did not think the data was strong enough to support approval. Chelsea’s shares fell as much as 36 percent following that review. They were halted during the panel meeting on Tuesday, and rose to $5.78 in after-hours trading from a close on Monday of $2.30  Northera, also known as droxidopa, is converted by the body into norepinephrine, a chemical messenger that sends signals to blood vessels and the heart to regulate blood pressure. Insufficient norepinephrine can lead to light-headedness and fainting upon standing. Chelsea originally filed for approval of droxidopa in 2011, based on a study known as 301. In February, 2012, an FDA advisory panel recommended approval of the drug, but the agency rejected it and asked for additional data. The company sought to address the FDA’s concerns using data from a different study known as 306B, but the FDA denied the request and said an additional trial would be needed. Chelsea appealed the decision, and in early 2013 the FDA agreed to accept a resubmission based on data from the 306B study, saying that while short-term data, if convincing, would be adequate for approval, a post-approval study could be required to prove the results were durable. Targum said the results of study 306B did not meet those criteria. Most panelists, however, said that while there was no convincing evidence that the drug provides a durable benefit, there was no convincing evidence to show that it does not show a benefit. “This is a terrible disease and there are no other effective medications,” said Dr. Vasilios Papademetriou, a cardiologist and professor of medicine at Georgetown University. Although the studies were not perfect, he said, “the data convinced me there is a long lasting benefit in some patients.”  Chelsea licensed rights to the drug outside Asia from Dainippon Sumitomo Pharma in 2006. It was introduced in Japan in 1989. Claim: FDA advisory panel backs Chelsea Therapeutics drug.
answer:

A drug to treat a rare form of low blood pressure made by Chelsea Therapeutics International Ltd is effective enough to warrant regulatory approval, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.